Algernon Pharmaceuticals has filed for orphan drug status for NP-120 (ifenprodil), an experimental oral medicine for patients with idiopathic pulmonary fibrosis (IPF) who have persistent, hard-to-treat cough. “The FDA has a standard response time of 90 days to requests for orphan designation, and so we should know by…
Orphan Drug Status Sought for NP-120 to Treat IPF With Cough
I’ve spent much of my working life conducting investigations. As a special agent for the Air Force Office of Special Investigations and in a second career providing security and investigative services under contract to the federal government, the cases all had similar objectives. Simply stated, any investigation needs to answer…
Treatment with Haduvio (nalbuphine extended-release tablets) significantly reduced coughing for people with idiopathic pulmonary fibrosis (IPF), according to top-line data from the Phase 2 CANAL trial. “It is very promising to see such a significant reduction in chronic cough in IPF patients with [Haduvio],” Peter Dicpinigaitis, MD, a professor…
A molecular test, called the Envisia Genomic Classifier, may predict which patients with idiopathic pulmonary fibrosis (IPF) will progress on immunosuppressants, which could help doctors decide who will more likely benefit from antifibrotic therapy. The test, developed by Veracyte, can tell IPF from other types of interstitial lung…
I wore a mask to protect myself from germs and viruses before it was required by the COVID-19 pandemic. After my diagnosis of idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening respiratory disease, in April 2016, I now do everything I can to protect my lungs. Unfortunately, I…
Shortly after my diagnosis of idiopathic pulmonary fibrosis (IPF) in January 2017, I spoke with my pulmonologist, Dr. Steven Nathan, about participating in research. One of the first projects I joined was the Pulmonary Fibrosis Foundation (PFF) Patient Registry. The PFF Patient Registry began following patients in 2016,…
The oral anti-fibrotic treatment Ofev (nintedanib) was found to be generally well-tolerated among children and adolescents with fibrosing interstitial lung diseases (ILDs) in the Phase 3 InPedILD clinical trial. “Data from the InPedILD trial demonstrate that [Ofev] has an acceptable safety and tolerability profile in children and adolescents with…
Patients receiving a higher dose of PLN-74809 in the Phase 2a INTEGRIS-IPF clinical trial, which is testing the oral treatment candidate for idiopathic pulmonary fibrosis (IPF), are showing positive safety outcomes. That’s according to data from a safety review analysis conducted by the study’s data safety monitoring board (DSMB)…
I’ve been writing this column for almost six years. Throughout that time, I’ve had the privilege of interacting with other patients living with idiopathic pulmonary fibrosis (IPF), a progressive and life-threatening lung disease. While IPF is considered a rare disease, it doesn’t always feel that way given how many…
NP-120 (ifenprodil), an investigational treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough, continues to demonstrate an ability to preserve lung function and ease cough, according to analyses of secondary goals in a Phase 2a trial. Most of these analyses related to patient-reported outcomes, supplementing positive top-line data from…
